CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
Open Access
- 16 March 2023
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 14 (12), 1089-1097
- https://doi.org/10.1111/1759-7714.14853
Abstract
Background: Thymic squamous cell carcinoma and type B3 thymoma are primary neoplasms of the anterior mediastinum that are sometimes difficult to differentiate from one another histologically. However, only a few immunohistochemical markers are available for the differential diagnosis. The purpose of this study was to discover a novel marker for differentiating between thymic squamous cell carcinoma and type B3 thymoma.Methods: We used histological samples of thymic carcinomas (n = 26) and type B3 thymomas (n = 38) which were resected between 1986 and 2017. To search for candidates of differential markers, gene expression levels were evaluated in samples using promoter analysis by cap analysis of gene expression (CAGE) sequencing.Results: Promoter level expression of CALML5 genes was significantly higher in thymic carcinomas than in type B3 thymomas. We further validated the results of the CAGE analysis in all 26 thymic carcinomas and 38 type B3 thymomas by immunohistochemistry (IHC). CALML5 was strongly expressed in the cytoplasm in 19 of 26 cases with thymic carcinoma, whereas positivity at the protein level was shown in two of 38 type B3 thymomas. Thus, the sensitivity (73.1%) and specificity (94.7%) of CALML5 as markers for immunohistochemical diagnosis of thymic carcinoma were extremely high.Conclusion: We identified CALML5 as a potential marker for differentiating thymic squamous cell carcinoma from type B3 thymoma. It is assumed that future clinical use of CALML5 may improve the diagnostic accuracy of differentiating between these two diseases.Keywords
Funding Information
- Japan Society for the Promotion of Science (18K08185)
This publication has 32 references indexed in Scilit:
- Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinomaInternational Journal of Experimental Pathology, 2010
- Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cellsOncogene, 2010
- Fast and accurate long-read alignment with Burrows–Wheeler transformBioinformatics, 2010
- Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasmsLaboratory Investigation, 2009
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- PAnnBuilder: an R package for assembling proteomic annotation dataBioinformatics, 2009
- Multiple inflammatory cytokine-productive ThyL-6 cell line established from a patient with thymic carcinomaCancer Science, 2008
- Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignanciesInternational Journal of Cancer, 2003
- Identification and Cloning of a New Calmodulin-like Protein from Human EpidermisOnline Journal of Public Health Informatics, 2000